Skip to main content

Clinical Trials

Study

GLY-200-03

A 16-Week study to evaluate the efficacy, safety, and tolerability of GLY-200 in participants with obesity

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants with Obesity

Status:
Ongoing

Study

GLY-200-02

Phase 2 study of safety, tolerability, and pharmacodynamic effects of GLY-200 in type 2 diabetic patients

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients

Status:
Completed

Study

GLY-200-01

Phase 1 study of safety and tolerability of GLY-200 in healthy volunteers

A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single & Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of GLY-200 in Healthy Adult Subjects

Status:
Completed

Close Menu

About Glyscend, Inc.

1812 Ashland Avenue, Suite 110
Baltimore, MD 21205, USA

600 Suffolk Street, Suite 250
Lowell, MA 01854-3643, USA